RPG Life Sciences Limited (RPGLIFE)
₹2,608.30 -6.18% today, as of 12:24 IST · NSE, refreshed every 5 minutes while the market is open
Q2 FY27 results
📅 Next results: 29 Oct 2026 (board meeting)RPG Life Sciences Limited's board meets on 29 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, Q1 FY27, RPG Life's revenue was ₹196 Cr (+15.8% year on year, +10.6% on the previous quarter), and net profit ₹30.8 Cr (+17.0% year on year); the operating margin was 22.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹196 | +15.8% | +10.6% |
| Operating profit | ₹43.3 | +22.0% | +31.2% |
| Net profit | ₹30.8 | +17.0% | +2.5% |
| EPS (₹) | 18.60 | +17.0% | +2.9% |
| Operating margin | 22.1% | — | — |
RPGLIFE delivery percentage
NSE end-of-day data for
On Thu, 22 Oct 2026, 38.7% of the RPGLIFE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 41.93%. That is close to its usual level. Volume was 0.3 times its average, well below normal.
Delivery in the last 5 sessions: 48.1% · 21.5% · 35.0% · 44.0% · 38.7%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
RPG Life Sciences Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar and Transfer Agent MUFG Intime India Private Limited on October 03, 2026, confirms that securities received for dematerialisation during the quarter ended September 30, 2026, were processed and confirmed within prescribed timelines. The dematerialised securities have been listed on the stock exchanges where earlier shares are listed. This is a standard quarterly administrative filing with no financial impact.
- Regulation 74(5) demat compliance confirmed for the quarter ended September 30, 2026
- Certificate issued by Registrar MUFG Intime India Private Limited on October 03, 2026
- Filing submitted to NSE and BSE on October 08, 2026
- All received share certificates were duly verified, mutilated, and cancelled as per timelines
RPG Life Sciences announced that its subsidiary, RPG Active Pharma Limited (RPGAP), has approved a Scheme of Amalgamation to absorb its wholly owned subsidiary, Actis Generics Private Limited. In FY26, Actis Generics recorded revenue of Rs 45.96 crore and a net worth of Rs 34.60 crore, while RPGAP reported no operational revenue and a net worth of Rs 34.75 crore. Because Actis is a wholly owned subsidiary of RPGAP, no new shares will be issued, and RPG Life Sciences' shareholding pattern remains unchanged. The merger aims to simplify the corporate structure, eliminate duplicate operational expenses, and consolidate active pharmaceutical ingredient (API) assets.
- Board of subsidiary RPG Active Pharma Limited approved the merger of its wholly owned subsidiary Actis Generics on September 25, 2026
- Actis Generics reported FY26 revenue from operations of Rs 45.96 crore and net worth of Rs 34.60 crore as of March 31, 2026
- RPGAP, incorporated on December 24, 2025, had nil revenue from operations and a net worth of Rs 34.75 crore
- Nil cash or share consideration as Actis is a wholly owned subsidiary; all transferor shares stand cancelled upon effectiveness
RPG Life Sciences Limited announced the completion of its acquisition of Actis Generics Private Limited on September 24, 2026. The transaction was executed via the company's subsidiary, RPG Active Pharma Limited (RPGAP), pursuant to a Share Purchase Agreement signed on July 29, 2026. Following this closure, Actis Generics has become a wholly owned subsidiary of RPGAP and a step-down subsidiary of RPG Life Sciences. Financial details, including the acquisition cost and enterprise value, were not disclosed in this update.
- Completed acquisition of entire stake (100%) in Actis Generics Private Limited on September 24, 2026
- Transaction conducted pursuant to the Share Purchase Agreement dated July 29, 2026
- Actis Generics is now a wholly owned subsidiary of RPG Active Pharma Limited (RPGAP) and subsidiary of RPG Life Sciences
- Financial consideration and valuation terms were not disclosed in the filing
RPG Life Sciences Limited has scheduled participation in the Anand Rathi G-200 Summit 2026 on September 22, 2026, starting at 10:00 AM IST. The event will take place physically in Mumbai and involve group as well as one-on-one meetings with institutional investors. The company stated that discussions will adhere to presentations already available on company and stock exchange websites, with no new unpublished price-sensitive information shared. This is a standard investor interaction intimation under SEBI Regulation 30.
- Scheduled date of meeting: September 22, 2026
- Meeting start time: 10.00 A.M. Onwards
- Event hosted by Anand Rathi (G-200 Summit 2026)
- Format comprises Mumbai physical group meet and one-on-one sessions
RPG Life Sciences announced that its wholly owned subsidiary, RPG Active Pharma Limited, has completed the acquisition of the Active Pharmaceutical Ingredients (APIs) and intermediates business of Raghava Life Sciences Private Limited. The transaction was structured as a slump sale via a Business Transfer Agreement (BTA) originally executed on September 2, 2026. The transfer of the API business becomes effective on September 16, 2026. The transaction value was not disclosed in this update, though it follows the company's inorganic expansion strategy funded through its strong balance sheet.
- Completion of Business Transfer Agreement (BTA) executed on September 2, 2026
- Acquisition executed by wholly owned subsidiary RPG Active Pharma Limited
- Acquired the API and intermediates business of Raghava Life Sciences via slump sale
- Transfer of API business effective from September 16, 2026
RPG Life Sciences announced that its subsidiary, RPG Active Pharma Limited (RPGAP), has allotted securities to India Life Sciences Fund IV Domestic and Vistaject Fund for a total consideration of ₹243.33 crores. The allotment constitutes a 40% equity stake in RPGAP, valuing the subsidiary at approximately ₹608 crores post-money. This capital infusion of ₹243.33 crores represents ~33% of RPG Life's TTM revenue (₹735 crore) and ~40% of its net worth (₹605 crore). RPGAP continues to remain a subsidiary of RPG Life Sciences following the transaction.
- Subsidiary RPGAP allotted securities for a total consideration of INR 243.33 crores on September 9, 2026
- Allotment represents a 40% equity share capital stake in RPGAP
- Investors are India Life Sciences Fund IV Domestic (ILSF) and Vistaject Fund (VJF)
- RPGAP continues to be a subsidiary of RPG Life Sciences post-allotment
RPG Life Sciences Limited has informed the exchanges that details pursuant to its Analyst/Institutional Investor call held on September 3, 2026, at 04:00 PM IST have been uploaded to the company website. The announcement is a routine compliance filing providing public access to the call discussion. The company currently has a market capitalization of ₹4,396 Cr and reported TTM revenues of ₹735 Cr with an operating profit margin of 21.1%.
- Analyst/Institutional call conducted on Thursday, September 3, 2026, at 04:00 PM (IST)
- Filing confirms availability of meet details on the company's investor relations website
- Follows earlier intimation letters dated September 2, 2026, and September 3, 2026
- Procedural compliance update under SEBI Listing Regulations
RPG Life Sciences Limited has submitted dial-in details for an investor and analyst conference call scheduled for September 3, 2026, at 4:00 PM IST. The call focuses specifically on an update regarding the company's Active Pharmaceutical Ingredients (API) business. The management will be represented by Managing Director Ashok Nair and Chief Financial Officer Amol Lone. The filing is an administrative intimation with no disclosed financial metrics or new commercial contracts.
- API business update call scheduled for Thursday, September 3, 2026, at 4:00 PM IST
- Company represented by Managing Director Ashok Nair and CFO Amol Lone
- Call organized in coordination with Dolat Capital Market Pvt. Ltd.
RPG Life Sciences announced the subsidiarization of its API business into RPG Active Pharma (RPGAP), in which PE firm InvAscent is investing ~₹243.33 Cr for a 40% stake (leaving RPGLife with 60%). RPGAP is simultaneously executing two strategic acquisitions totaling ~₹215 Cr: Actis Generics for ~₹80 Cr and Raghava Life Sciences for ~₹135 Cr. The acquisitions expand installed API capacity by 4x (adding 300 KL capacity at Raghava with ~₹200 Cr revenue potential), creating an integrated API platform alongside FY26 external API sales of ~₹95.1 Cr.
- InvAscent investing ~₹243.33 Cr for a 40% primary equity stake in newly subsidiarized API entity RPGAP.
- RPGAP acquiring 100% of Actis Generics for ~₹80 Cr (incl. NWC) to add Anti-Diabetic and Cardiology API portfolios.
- RPGAP acquiring Raghava Life Sciences via slump sale for ~₹135 Cr, adding 300 KL capacity with ~₹200 Cr revenue potential.
- Total combined acquisition outlay of ~₹215 Cr represents ~29.3% of RPGLife's TTM revenue of ₹735 Cr.
- API unit had FY26 external third-party sales of ~95.1 Cr INR prior to the carve-out.
RPG Life Sciences has scheduled a virtual group investor/analyst call on Thursday, September 3, 2026, at 04:00 PM IST. The call is being hosted at short notice following the company's strategic announcement and Board meeting outcome dated September 2, 2026. Dial-in details and the investor presentation are to be shared separately on the stock exchanges and company website.
- Virtual group investor/analyst call scheduled for September 3, 2026, at 04:00 PM IST
- Call called at short notice in reference to the Board meeting outcome and strategic press release dated September 2, 2026
- Investor presentation and dial-in details to be submitted separately
RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has entered into a Business Transfer Agreement to acquire the API and intermediates business of Raghava Life Sciences for up to ₹135 crore on a slump-sale basis. The acquisition adds an EU-GMP and WHO-GMP approved facility near Hyderabad with ~300 KL installed capacity across 9 acres. The transaction brings a portfolio of 22 commercialized APIs and 7 development-stage molecules across cardiovascular, diabetes, and CNS segments. At up to ₹135 crore, the deal value represents ~18.4% of RPG Life Sciences' TTM revenue (₹735 crore) and ~22.3% of its net worth (₹605 crore).
- Acquisition of API and intermediates business undertaking for up to ₹135 crore via slump sale
- Adds ~300 KL installed capacity across a 9-acre EU-GMP/WHO-GMP approved facility near Hyderabad
- Expands portfolio with 22 commercialized APIs and 7 development-stage assets across diabetes, CNS, and cardiovascular therapies
- Secures international regulatory credentials including CEP, EU Written Confirmation, and KDMF approvals
RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited, has executed a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (APIs) and intermediates business of Raghava Life Sciences for up to ₹135 crore in cash. The acquired undertaking reported unaudited revenues of approximately ₹19 crore in FY26 and includes manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules (22 commercialized and 7 in development). The transaction represents ~22.3% of RPG Life's net worth (₹605 crore) and is expected to close within 30 days subject to closing conditions and regulatory approvals.
- Acquisition of API and intermediates business via slump sale for a cash consideration of up to ₹135 crore
- Target business generated ~₹19 crore revenue in FY26 (unaudited)
- Includes manufacturing and R&D facilities plus 29 API molecules (22 commercialized, 7 under development)
- Expected completion tentatively within 30 days, subject to closing conditions and regulatory approvals
RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited, has approved a Business Transfer Agreement to acquire the API and Intermediates business of Raghava Life Sciences for up to ₹135 crore in cash. The acquired business undertaking generated approximately ₹19 crore in revenue during FY26 and includes manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules (22 commercialized and 7 under development). The deal consideration represents approximately 22.3% of RPG Life's net worth (₹605 crore) and 18.4% of TTM revenue (₹735 crore). The transaction is slated to close within 30 days, subject to closing conditions and local regulatory approvals.
- Total cash consideration of up to ₹135 crore for the API and intermediates business via slump sale
- Acquiring business generated ~₹19 crore in revenue in FY26 (unaudited)
- Includes manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules (22 commercialized, 7 under development)
- Expected deal completion within tentatively 30 days
RPG Life Sciences Limited has informed the exchanges that the Investors/Analysts meet scheduled for Wednesday, September 2, 2026, at 10:00 a.m. onwards stands cancelled. The meeting was previously intimated via an exchange letter dated August 25, 2026. This is a routine administrative disclosure under Regulation 30 of SEBI LODR and carries no direct financial or operational implications.
- Investor/Analyst meet scheduled for September 2, 2026, at 10:00 a.m. onwards is cancelled
- Prior intimation for the meet was submitted on August 25, 2026
- Disclosure filed pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
RPG Life Sciences Limited has announced its participation in the 'Ashwamedh – Elara India Dialogue 2026' investor conference on September 02, 2026. The physical event in Mumbai will involve both group and one-on-one meetings starting at 10:00 AM IST. The company confirmed that any presentations made will strictly adhere to existing disclosures already available on stock exchange websites.
- Meeting date: September 02, 2026, starting from 10.00 A.M. IST onwards.
- Host/Event: Ashwamedh – Elara India Dialogue 2026 in Mumbai.
- Format: Physical meeting consisting of group and one-on-one sessions.
- Presentations will align with disclosures already available on company and stock exchange portals.
Financial Performance
Revenue Growth by Segment
Domestic Formulations grew 10.1% YoY to INR 425.00 Cr in FY25. Overall revenue showed a 5-year CAGR of ~12% ending FY24, with 13% growth in FY24 and 12% in 9M FY25. Q2 FY26 revenue reached INR 181.7 Cr, a 7.6% increase over Q1 FY26.
Geographic Revenue Split
Domestic Formulations is the primary driver, contributing ~67% of total revenue in FY24. The remaining 33% is derived from International Formulations and API segments across regulated markets like the EU, Australia, and Japan.
Profitability Margins
Operating Profit Margin (OPM) improved from 19.8% in FY22 to 20.4% in FY23, 22.2% in FY24, and reached 26.3% in 9M FY25. PAT margin stood at 15.6% in Q2 FY26 (INR 28.5 Cr).
EBITDA Margin
EBITDA margin was 24.0% in Q2 FY26 (INR 43.6 Cr), up from 21.0% in Q1 FY26. The 5-year OPBIDTA CAGR is ~29%, reflecting significant operational scaling and cost optimization.
Capital Expenditure
The company has no major debt-funded capex plans. Recent investments focused on modernizing manufacturing plants and capacity enhancements. Liquidity was bolstered by monetizing surplus land at the API plant in February 2025.
Credit Rating & Borrowing
Long-term rating upgraded to [ICRA]A+ (Stable) in March 2024 from [ICRA]A (Stable). Short-term rating reaffirmed at [ICRA]A1. The company is virtually debt-free with a Total Debt/OPBDITA of 0.004x as of September 2022.
Operational Drivers
Raw Materials
Bulk drugs and intermediates for API and formulation manufacturing. Specific names not listed, but they include inputs for immunosuppressants and anti-diarrheals.
Import Sources
Significant portion of raw materials and intermediates are dependent on imports, particularly for the API segment, making margins sensitive to global price volatility.
Key Suppliers
Not specifically named in documents; however, the company monitors concentration of purchases with trading houses and related parties.
Capacity Expansion
Capacity enhancements are ongoing to support a 12% revenue CAGR. The company has modernized both manufacturing plants to secure international regulatory approvals.
Raw Material Costs
Margins are susceptible to raw material price fluctuations. Procurement strategies focus on cost rationalization and optimizing the product mix toward higher-margin international formulations.
Manufacturing Efficiency
Efficiency is driven by cost rationalization and a shift toward high-margin specialty products. Operating margins reached a peak of 26.3% in 9M FY25 due to these measures.
Logistics & Distribution
The company is expanding its field force and deploying digital solutions to enhance sales force effectiveness and distribution reach in targeted therapies.
Strategic Growth
Expected Growth Rate
12%
Growth Strategy
Growth is targeted through five pillars: Product Portfolio Rejuvenation (building chronic/specialty portfolios), Strategic Brand Asset Building (life cycle management), Customer Coverage Deepening (expanding field force), Sales Force Effectiveness, and Profitability Improvement (optimizing manufacturing).
Products & Services
Pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) for Nephrology (immunosuppressants), Gastro-intestinal (anti-diarrheal), Pain Management, Cardiovascular, Oncology, and Rheumatology.
Brand Portfolio
Not specifically listed by name, but the company relies on a few 'top brands' in the domestic market which drive the majority of revenue.
New Products/Services
Launched 12 new products in FY24 and 17 in 9M FY25. Sales from new products launched since FY19 now contribute ~25% of total domestic formulation sales.
Market Expansion
Focusing on increasing presence in existing geographies and exploring new markets after re-evaluating and deferring US market entry.
Market Share & Ranking
Holds strong market share in niche therapeutic segments like Nephrology (immunosuppressants) and Gastro-intestinal (anti-diarrheal).
Strategic Alliances
Exited biotech API segment via a slump sale to Intas Pharmaceuticals Limited in 2016 for INR 25.0 Cr to focus on core formulations.
External Factors
Industry Trends
The industry is shifting toward chronic and specialty therapies. RPGLS is positioning itself by rejuvenating its portfolio in these high-growth areas and maintaining global manufacturing compliance.
Competitive Landscape
Operates as a mid-sized player facing competition from both large Indian pharma companies and multinational corporations in regulated markets.
Competitive Moat
Moat is built on strong brand equity in specialized therapies (Nephrology) and a debt-free balance sheet providing high financial flexibility. Sustainability is supported by the RPG Group lineage.
Macro Economic Sensitivity
Sensitive to economic developments in India and changes in demand/supply conditions within the global pharmaceutical industry.
Consumer Behavior
Increasing demand for chronic disease management and specialty medicines is driving the company's shift toward these portfolios.
Geopolitical Risks
Trade barriers or regulatory changes in export markets (EU, Australia, Japan) could impact the international formulations business.
Regulatory & Governance
Industry Regulations
Strict adherence to EU GMP, WHO GMP, TGA Australia, PMDA Japan, and NDPS certifications. Susceptible to social risks related to product safety and government price controls.
Taxation Policy Impact
Subject to Indian corporate tax laws and international tax regulations for export revenue.
Legal Contingencies
No fines or penalties related to corruption or conflict of interest were reported for FY25. Secretarial audit is conducted to ensure compliance with statutory records.
Risk Analysis
Key Uncertainties
Adverse regulatory observations from health authorities could impact manufacturing and profitability. Sustained deterioration in RoCE below 16% is a key rating monitorable.
Geographic Concentration Risk
67% of revenue is concentrated in the Indian domestic market, making it sensitive to local regulatory and economic shifts.
Third Party Dependencies
Dependency on external suppliers for imported raw materials and intermediates poses a risk to margin stability.
Technology Obsolescence Risk
The company is mitigating technology risks by modernizing plants and deploying digital solutions for sales force effectiveness.
Credit & Counterparty Risk
Receivables quality is supported by a stable working capital cycle and strong liquidity, with cash and liquid investments of INR 126 Cr as of Sept 2024.
